Phase 3 Clinical Trials With Primary Completion Dates in December 2015
This is a list of Phase 3 trials with primary completion dates in December 2015 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2015-12-01 | Phase 3 | NCT00550238 | A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis |
| ACRX | AcelRx Pharmaceuticals, Inc. | 2015-12-01 | Phase 3 | NCT02447848 | A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of a Sublingual Sufentanil Tablet 30 mcg for the Treatment of Acute Pain |
| ATOS | Atossa Genetics Inc. | 2015-12-01 | Phase 3 | NCT02539615 | A Trial of the ForeCYTE Breast Aspirator for Cytological Testing of Nipple Aspirate Fluid in Women 30-55 Years Old |
| BDSI | BioDelivery Sciences International, Inc. | 2015-12-01 | Phase 3 | NCT02516436 | The Safety of Using Buprenorphine With Naloxone in a Buccal Film to Initiate Treatment of Opioid Dependent Subjects |
| CBYL | Carbylan Therapeutics, Inc. | 2015-12-01 | Phase 3 | NCT02022930 | Hydros and Hydros-TA Joint Therapy for Pain Associated With Knee Osteoarthritis |
| CTIC | CTI BioPharma Corp. | 2015-12-01 | Phase 3 | NCT02055781 | Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia |
| CTIC | CTI BioPharma Corp. | 2015-12-01 | Phase 3 | NCT01321541 | Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant |
| CVM | Cel-Sci Corporation | 2015-12-01 | Phase 3 | NCT01265849 | Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity |
| DPRX | Dipexium Pharmaceuticals, Inc. | 2015-12-01 | Phase 3 | NCT01594762 | Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers |
| DPRX | Dipexium Pharmaceuticals, Inc. | 2015-12-01 | Phase 3 | NCT01590758 | Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers |
| DVAX | Dynavax Technologies Corporation | 2015-12-01 | Phase 3 | NCT02117934 | Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine |
| ICLR | ICON plc | 2015-12-01 | Phase 3 | NCT02547623 | Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery |
| LIVN | LivaNova PLC | 2015-12-01 | Phase 3 | NCT01534234 | Clinical Trial of the SonRtip Lead and Automatic AV-VV Optimization Algorithm in the PARADYM RF SonR CRT-D |
| MSTX | Mast Therapeutics, Inc. | 2015-12-01 | Phase 3 | NCT01737814 | Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC) |
| ONTX | Onconova Therapeutics, Inc. | 2015-12-01 | Phase 3 | NCT01928537 | Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine |
| PCRX | Pacira Pharmaceuticals, Inc. | 2015-12-01 | Phase 3 | NCT02517905 | Evaluation of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction |
| PEN | Penumbra, Inc. | 2015-12-01 | Phase 3 | NCT01636453 | The Penumbra Liberty Trial: Safety and Effectiveness in the Treatment of Wide-Neck Intracranial Aneurysms |
| PTLA | Portola Pharmaceuticals, Inc. | 2015-12-01 | Phase 3 | NCT01583218 | Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study) |
| RARE | Ultragenyx Pharmaceutical Inc. | 2015-12-01 | Phase 3 | NCT02230566 | A Phase 3 Study of UX003 rhGUS Enzyme Replacement Therapy in Patients With MPS 7 |
| RMD | ResMed Inc. | 2015-12-01 | Phase 3 | NCT00738179 | Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea to Prevent Cardiovascular Disease |
| RPTP | Raptor Pharmaceutical Corp. | 2015-12-01 | Phase 3 | NCT01197378 | Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) |
| SGYP | Synergy Pharmaceuticals, Inc. | 2015-12-01 | Phase 3 | NCT01919697 | Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC) |
| SGYPU | Synergy Pharmaceuticals, Inc. | 2015-12-01 | Phase 3 | NCT01919697 | Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC) |
| SPPI | Spectrum Pharmaceuticals, Inc. | 2015-12-01 | Phase 3 | NCT01469221 | Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) |
| SPPI | Spectrum Pharmaceuticals, Inc. | 2015-12-01 | Phase 3 | NCT01410565 | Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer |
| TSRO | TESARO, Inc. | 2015-12-01 | Phase 3 | NCT01905592 | A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients |
| VNDA | Vanda Pharmaceuticals Inc. | 2015-12-01 | Phase 3 | NCT01291511 | Relapse Prevention Study in Patients With Schizophrenia |